Corporate team

Our 23-strong team boasts deep experience in RNA biology, bioinformatics analytics, neuro-translation and development.

Dr Jan Thirkettle

CEO

Dr Madeleine Wakeling

COO

Dr Andy Billinton

CSO

Mandy Cowling

EA, Office Manager and HR Lead

Our programmes

Huntington's Disease

ALS and Alzheimer's

Our news

February 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

Read more

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

Read more

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

Read more

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

Read more